Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 28, 2015
GERMLINE DELETION OF ARMC5 IN FAMILIAL PRIMARY MACRONODULAR ADRENAL HYPERPLASIASawako Suzuki, Ichiro Tatsuno, Emi Oohara, et al.
Communications Biology|July 28, 2023
Identification of genotype-biochemical phenotype correlations associated with fructose 1,6-bisphosphatase deficiencyIkki Sakuma, Hidekazu Nagano, Naoko Hashimoto, et al.
Cell Reports|June 3, 2026
CIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severityIkki Sakuma, Rafael C Gaspar, Henrique N Morgan, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2023
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitisPanu K Luukkonen, Ikki Sakuma, Rafael C Gaspar, et al.
The Journal of Clinical Endocrinology and Metabolism|October 20, 2019
Aldosterone Reduction Rate After Saline Infusion Test May Be a Novel Prediction in Patients With Primary AldosteronismHidekazu Nagano, Takashi Kono, Atsushi Saiga, et al.
Internal Medicine (Tokyo, Japan)|November 3, 2017
Prednisolone-responsive Postpartum IgG4-related HypophysitisHisashi Koide, Akina Shiga, Eri Komai, et al.
Nature Communications|May 19, 2026
Western diet-induced MASH in PWK/PhJ mice identifies disruptions in amino acid and sphingolipid metabolism contributing to cardiac dysfunctionSandra Rodríguez-López, Miguel Pérez-Rodríguez, Alaa Badreddine, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 2025
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitisIkki Sakuma, Rafael C Gaspar, Ali R Nasiri, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitisIkki Sakuma, Rafael C Gaspar, Ali R Nasiri, et al.
Nature Communications|March 26, 2026
LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLCTakumitsu Machida, Yingbo Gong, Sayaka Tsukioka, et al.
Pageof 5